Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 3,600 shares, a growth of 3,500.0% from the March 31st total of 100 shares. Currently, 0.0% of the company's shares are short sold. Based on an average daily volume of 100 shares, the short-interest ratio is currently 36.0 days.
Basilea Pharmaceutica Stock Performance
Shares of BPMUF stock remained flat at $47.50 on Friday. The stock's 50 day moving average price is $52.58 and its 200-day moving average price is $52.72. Basilea Pharmaceutica has a fifty-two week low of $47.50 and a fifty-two week high of $54.00. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10.
About Basilea Pharmaceutica
(
Get Free Report)
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Basilea Pharmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.
While Basilea Pharmaceutica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
